Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, considers whether the results of ReDOS study have allowed for more effective dosing of regorafenib in the management of advanced colorectal cancer (CRC) patients

Published: 22 January 2019

Recent Videos: Colorectal

video

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, offers ...

video

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares his impression of the CCTG CO.26 trial comparing durvalumab plus ...

video

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, considers whether the results of ReDOS study have allowed for more ...

video

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares details regarding patient selection and treatment algorithms in the management ...

video

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, tells ...

video

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, on whether circulating tumor DNA (ctDNA) is a valid surrogate for ...

video

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, ...

video

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, explains how next generation sequencing (NGS) fits into diagnosis and treatment ...

video

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, ...

video

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, shares thoughts on genetic testing ...

Related Videos

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

video-image

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

video-image

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

video-image

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

video-image

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

video-image

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

video-image

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

video-image

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

video-image

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC

video-image

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

video-image

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

video-image

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

video-image

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

video-image

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

video-image

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

video-image

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

video-image

Howard Hochster, MD, regarding the role of genetic testing in mCRC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

video-image

Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

video-image

Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma

video-image

Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma

video-image

Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC